Evidence map›Paper›PMID 40826392›Full record

Trial reportBMC nephrology2025

The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial.

Amira Reda Muhammad Galal, Nahla Mohamed Teama, Karema Abu-Elfotuha, Ahmed D Alatawi, Hanan Alshareef, Ahmed M E Hamdan, Ahmed Aljabri, Mohannad Alshibani, Zeinab AlKasaby Mahmoud Zalat

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05284656 (The Potential Nephro-protective Effect of Folic Acid and/or Pentoxifylline on Patients With Chronic Kidney Disease), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05284656 phase3active not recruitingnot on this map

The Potential Nephro-protective Effect of Folic Acid and/or Pentoxifylline on Patients With Chronic Kidney Disease

TypeinterventionalSponsorAl-Azhar UniversityRan2022 to 2026Enrolled80ConditionsChronic Kidney DiseasesArmscombination of Pentoxifylline 400 MG and Folic Acid, folic acid, Pentoxifylline 400 MG
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amira Reda Muhammad GalalDepartment of Clinical Pharmacy, Faculty of Pharmacy (Girls), Al Azhar University, Cairo, Egypt.
Nahla Mohamed TeamaDepartment of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Karema Abu-ElfotuhaDepartment of Clinical Pharmacy, Faculty of Pharmacy (Girls), Al Azhar University, Cairo, Egypt.ORCID 0000-0003-3870-3206
Ahmed D AlatawiDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Hanan AlshareefDepartment of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, 74191, Saudi Arabia.ORCID 0000-0002-1264-7229
Ahmed M E HamdanDepartment of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, 74191, Saudi Arabia. a_hamdan@ut.edu.sa.ORCID 0000-0003-4930-792X
Ahmed AljabriDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0002-7049-9826
Mohannad AlshibaniDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Zeinab AlKasaby Mahmoud ZalatDepartment of Clinical Pharmacy, Faculty of Pharmacy (Girls), Al Azhar University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesChronic kidney disease (CKD) is a highly prevalent, irreversible, and progressive disease associated with a high cardiovascular risk. We aimed to clinically investigate the extra-therapeutic effect of adding therapeutic doses of pentoxifylline (PTX) and/or folic acid (FA) for CKD patients to the standard care on their health-related quality.

methodsA randomized, prospective, parallel, and controlled clinical trial of CONSORT 80 patients diagnosed with CKD stages 3-5 were stratified by simple randomization into four groups (20 patient/group) and followed up for 6 months. CONTROL GROUP: received standard usual care therapy only; PTX group: received therapeutic dose of PTX added to standard usual care therapy; FA group: received FA added to standard usual care therapy; and PTX and FA group: received both PTX and FA added to their standard usual care therapy. The primary objective was to compare the renal function biochemical parameters for the intervention groups compared to the control group. Meanwhile, the secondary objective was to compare the incidence of readmission to hospitalization with cardiovascular events, incidence of peripheral vascular diseases and Fatigue Assessment Scale (FAS) for the intervention groups compared to the control group. CLINICAL

trial registrationThis study's research was granted authorization by the Research Ethics Committee (REC), Faculty of Medicine, Ain Shams University, No. (FMASU MS UNIV 15/2022) dated to 15/12/2022, and the Ethical Committee in the Faculty of Pharmacy (Girls), Al-Azhar University, No. (313) dated to 22/12/2022. This study was authorized by https://clinicaltrials.gov/ (NCT05284656) and the first date of registration was 16/02/2022. All patients were assigned to write an informed consent.

resultsThere was a significant improvement in renal function biochemical parameters and a significant reduction in the FAS for the intervention groups compared to the control group.

conclusionsOur results demonstrated that administration of therapeutic doses of PTX and/or FA in CKD patients delayed the progression of advanced chronic kidney disease and has been used successfully improved their health-related quality of life.

Indexed as

Folic AcidPentoxifyllineRenal Insufficiency, ChronicAdultAgedCardiovascular DiseasesDrug Therapy, CombinationFemaleHumansMaleMiddle AgedProspective StudiesQuality of LifeTreatment OutcomeFolic AcidPentoxifyllineAnemiaChronic kidney diseaseClinical trialsFolic acidPentoxifyllineRenal function parameters

Identifiers

PMID40826392
PMCPMC12363063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.